[Suzuken] Revised Medium-Term Management Plan and Management with Capital Cost Awareness｜May 2026

Performance Overview

Suzuken has formulated a medium-term management plan covering fiscal years ending in March 2027 through 2029, with an ultimate goal of achieving an ROE of 8%. The plan emphasizes responding to changes in the healthcare and pharmaceutical industries, focusing on evolving into the next-generation distributor, redesigning the business portfolio, and strengthening the management foundation. Although specific figures for sales and net profit are not disclosed, the ROE, excluding gains from the sale of policy-held shares, is in the 6% range and still improving. The company aims to generate stable profits exceeding its cost of capital to sustainably enhance corporate value.

Future Outlook and Strategies

Suzuken views environmental changes as growth opportunities and will promote evolution into the next-generation distributor and redesign its business portfolio. It will particularly focus on ensuring stable supply, improving efficiency, and providing services that receive appropriate compensation for value created. Human resource development and digital transformation are also key initiatives, with efforts aimed at harnessing diverse talents and strengthening the management foundation for sustained growth. The company will continue to manage with a focus on capital costs and stock prices, aiming to improve its PBR.